Wiggins C A, Dykewicz M S, Patterson R
Department of Medicine, Northwestern University Medical School, Chicago, Ill.
J Allergy Clin Immunol. 1989 Sep;84(3):311-5. doi: 10.1016/0091-6749(89)90413-2.
Idiopathic anaphylaxis (IA) is a life-threatening disease that is being increasingly recognized. In patients with frequent episodes of anaphylaxis, prednisone controls the events and then either induces remission or suppresses the manifestations of the disease until a spontaneous remission occurs. We report five patients with IA who have recurrent episodes whenever prednisone is tapered below a threshold dose, ranging from 15 to 65 mg every other day. These patients demonstrate the concept of a threshold dose of prednisone that may exist in a subset of patients with IA, and they provide further evidence of the previously reported efficacy of corticosteroids in the treatment of IA. We use the term corticosteroid-dependent IA to refer to the serious problem of chronic IA requiring maintenance prednisone therapy.
特发性过敏反应(IA)是一种日益受到认可的危及生命的疾病。在过敏反应频繁发作的患者中,泼尼松可控制病情发作,随后诱导缓解或抑制疾病表现,直至自发缓解。我们报告了5例IA患者,每当泼尼松减至低于阈值剂量(每隔一天15至65毫克)时,就会复发。这些患者证明了IA患者亚组中可能存在泼尼松阈值剂量的概念,并进一步证明了先前报道的皮质类固醇治疗IA的疗效。我们使用“皮质类固醇依赖型IA”一词来指代需要维持泼尼松治疗的慢性IA这一严重问题。